X

Immuno Oncology

Immuno Oncology

Immunotherapy Combination Confers Durable Benefit in Advanced Renal Cell Carcinoma

First-line nivolumab plus ipilimumab conferred greater long-term clinical benefit than sunitinib for patients with advanced renal cell carcinoma, according to new study results. 

Healio
11/16/2021
SSTP1, a Host Defense Peptide, Exploits the Immunomodulatory IL6 Pathway to Induce Apoptosis in Cancer Cells

Researchers suggests that identification of the membrane targets for the promising anticancer HDPs might lead to the identification of new drugs for targeted therapy.

Frontiers in Immunology
11/19/2021
Role of Immunotherapy in Localized Muscle Invasive Urothelial Cancer

Study investigators report results from clinical trials using single agent ICI, ICI/ICI and ICI/chemo combination therapies in the neoadjuvant setting for non-metastatic MIBC. 

Therapeutic Advances in Medical Oncology
09/22/2021

Response Endpoints Deemed ‘Poor Surrogates’ for Overall Survival in Trials of Immune Checkpoint Inhibitors

Tumor response endpoints are “poor surrogate endpoints” for OS in trials of immune checkpoint inhibitors, according to research published in JCO Precision Oncology.

Cancer Therapy Advisor
08/05/2021
Comprehensive Transcriptomic Analysis Reveals the Role of the Immune Checkpoint HLA-G Molecule in Cancers

The aim of this study is to systematically identify the roles of checkpoint HLA-G molecules across various types of cancer.

Frontiers in Immunology
07/01/2021
Cardiovascular Risks Associated With Checkpoint Inhibitors and CAR T-Cell Therapy

Leveraging the immune system to treat cancer, however, also increases the potential for serious off-target effects.

The ASCO Post
04/10/2021
Standardization & Harmonization of Immuno-Oncology Toxicities

A report from the Association of Community Cancer Centers shows that IO treatment is increasingly being given to patients in community settings, not just in academic cancer centers.

Oncology Times - Latest Articles
04/05/2021
mRNA in Cancer Immunotherapy: Beyond a Source of Antigen

Many novel immunotherapeutic strategies focus on the use of mRNA beyond its use as the source of tumor antigens. 

Molecular Cancer
03/03/2021
Immune Regulation of the cGAS-STING Signaling Pathway in the Tumor Microenvironment and Its Clinical Application

STING agonists, as novel agonists, are used in preclinical research and in the treatment of various tumors via clinical trials and have displayed attractive application prospects.

OncoTargets and Therapy
03/01/2021
Clinical Sequencing to Assess Tumor Mutational Burden as a Useful Biomarker to Immunotherapy in Various Solid Tumors

Tumor mutational burden has been considered as a useful marker to indicate patients who benefit from ICIs.

Therapeutic Advances in Medical Oncology
02/26/2021
The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy

This review focuses on m6A-associated regulation, mechanisms, and functions in acquired chemoresistance, radioresistance, and resistance to immunotherapy in cancer.

Frontiers in Oncology
02/25/2021
A Small-Molecule P2RX7 Activator Promotes Anti-Tumor Immune Responses and Sensitizes Lung Tumor to Immunotherapy

Only a subpopulation of NSCLC patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome.

01/28/2021
Radiotherapy–Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?

This review assesses the important clinical questions that need to be addressed to successfully combine radiotherapy and immunotherapy treatments by rethinking approaches to...

Cancers
01/26/2021
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies

Efforts to understand mechanisms of resistance and increase efficacy of immune checkpoint blockade in pancreatic cancer require the use of appropriate preclinical models in the laboratory.

Cancers
01/25/2021
Comprehensive Characterization of Immunological Profiles and Clinical Significance in Hepatocellular Carcinoma

Therapies targeting immune molecules have rapidly been adopted and advanced the treatment of hepatocellular carcinoma. 

Frontiers in Oncology
01/22/2021
Immuno-oncology: Are TAM Receptors in Glioblastoma Friends or Foes?

In this study, investigators aim to cast a spotlight on the potential multidirectional effects of TAM receptors in glioblastoma and provide a better understanding for TAM receptor-related targeted

01/28/2021
The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma

The aim of this review article is to characterize the profile of efficacy and safety of immuno-oncology-based monotherapies that failed to demonstrate significant benefit...

Cancers
01/11/2021
Targeting Hypoxia in the Tumor Microenvironment: A Potential Strategy to Improve Cancer Immunotherapy

In this review, the potential impact of hypoxia within the TME, in terms of key immune cell populations, and the contribution to immune suppression are discussed.

01/09/2021
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy

The role of the biochemical pathway of antigen presentation in cancer and how it can be modulated to enhance the efficacy of cancer immunotherapy is discussed.

Cancers
01/04/2021
PET Imaging Facilitates Antibody Screening for Synergistic Radioimmunotherapy With a 177Lu-Labeled αPD-L1 Antibody

The low response rate of immunotherapy, such as anti-PD-L1/PD-1 and anti-CTLA4, has limited its application to a wider population of cancer patients.

01/01/2021
Immunocyte Membrane-Coated Nanoparticles for Cancer Immunotherapy

This review shows the latest research progress, the advantages, the disadvantages, and the application of immunocyte membrane-coated nanoparticles in cancer immunotherapy.

Cancers
12/30/2020
The Microbiome and Its Implications in Cancer Immunotherapy

This review mainly focuses on various microbes and their association with different types of cancer, responses to immunotherapeutic modulation...

Molecules
01/03/2021
Society for Immunotherapy of Cancer Clinical Practice Guideline on Immunotherapy for the Treatment of Lymphoma

The recent development and clinical implementation of novel immunotherapies for the treatment of Hodgkin and non-Hodgkin lymphoma have improved patient outcomes across subgroups.

12/24/2020
`
Noninvasive Imaging of Cancer Immunotherapy

This study reviews recent developments in the field of noninvasive cancer imaging with a focus on immunotherapeutics and nuclear imaging technologies.

01/01/2021
Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer...

12/07/2020
Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee

Immunotherapy is now a cornerstone for cancer treatment, and much attention has been placed on the identification of prognostic and predictive biomarker.

11/16/2020
The evolving landscape of predictive biomarkers in immuno‐oncology with a focus on spatial technologies

This review aims to provide an overview of the current methodologies that are used to profile the TME, which may provide insights into the immunopathology associated...

11/22/2020
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

The B cell surface antigen CD19 is a target for treating malignancies, such as precursor acute lymphoblastic leukemia and non-Hodgkin lymphoma.

Annals of Hematology
08/27/2020
Immuno-oncology cell therapy branches out

Optimization of CAR-T cell technology and application other immune types such as NK cells are tackling the efficacy, cost logistical challenges therapies for cancer....

Biopharma Dealmakers
09/01/2020
Design considerations for phase I/II dose finding clinical trials in Immuno-oncology and cell therapy

Immuno-oncology and cell therapy, the frontier of cancer treatment, is a rapidly developing area that brings new opportunities to patients.

Contemporary Clinical Trials
09/01/2020
TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.

Conventional dose finding designs in oncology drug development target on the identification of maximum tolerated (MTD), with assumption that MTD has...

Journal of Biopharmaceutical Statistics
09/20/2020
Epigenetic Regulation of the Non-Coding Genome: Opportunities for Immuno-Oncology

The contribution of the non-coding genome to disease and its therapeutic potential have been largely unexplored. Recently, several epigenetic drugs developed for cancer treatment described...

Epigenomes
09/10/2020

source list reference

rgb(171, 222, 222)
#7d60d9
rgb(219, 18, 118)
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
rgb (247, 7, 79)
#352625
#4d4537
rgb(14, 133, 237)
rgb(252, 3, 223)
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
rgb(252, 186, 3)
#d2093c
#8e3f1c
rgb(242, 0, 137)
rgb (247, 7, 79)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
rgb (252, 186, 3)
#c61417
rgb(156, 242, 7)
rgb(91, 128, 189)
rgb(247, 139, 109)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(20, 13, 222)
rgb(84, 54, 94)
rgb(80, 147, 199)
rgb(117, 2, 247)
rgb(153, 146, 129)
#cc529a
#c59445
#c8cc0c
#bf6be3
rgb (245, 152, 2)
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
rgb(169, 196, 201)
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
rgb (191, 171, 145)
#89f67c
#49a21d
rgb(126, 14, 237)
rbg(167, 124, 235)
rgb (132, 101, 173)
#2c990a
rbg(16, 162, 230)
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
rgb(224, 224, 4)
#a60538
rgb(2, 230, 230)
rgb(186, 130, 237)
rgb(235, 64, 52)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834